【 文献重点摘要 】
 

Background: Botulinum toxin type A remains the most popular nonsurgical aesthetic treatment worldwide. Previous consensus statements have focused on Caucasians and on Koreans as generally representative of Asians. However, indications and dosages vary among different ethnic groups. This publication reports the results of a multidisciplinary, pan-Asian consensus focusing on incobotulinumtoxinA.

Methods: A consensus group of plastic surgeons and dermatologists from Asia, Europe, and the United States convened for a live meeting in Asia, followed by a questionnaire-based Delphi procedure. Treatment of Asians in both their native countries and countries of migration was discussed.

Results: For most items, the group achieved a majority consensus. A number of treatment indications, strategies, and dosages were identified in Asians, which are distinct to those previously described for Caucasians due to differences in facial morphotypes, anatomy, and cultural expectations. The group also formulated position statements for intradermal botulinum toxin type A (“mesotoxin”), body shaping with the calves as a paradigm, and reduction of parotid glands. While Asians have previously been considered a homogeneous group for the purposes of aesthetic treatment, this publication considers regional variations. A new classification of Asian facial morphotypes is proposed to aid treatment planning and implementation.

Conclusions: This is the first pan-Asian consensus for aesthetic use of botulinum toxin type A. Its unique objective is to optimize treatment safety and efficacy for patients of complete or part-Asian ancestry in all regions. The recommendations for incobotulinumtoxinA may be extended with care to other botulinum toxin formulations.

背景：A型肉毒毒素仍然是全世界最受欢迎的非手术美容疗法。此前的共识声明将重点放在高加索人和韩国人身上，认为他们通常代表亚洲人。然而，适应症和剂量在不同的种族之间有所不同。本出版物报道了一项多学科、泛亚洲共识的结果，该共识的重点是incobotulinumtoxinA。

方法：来自亚洲、欧洲和美国的整形外科医生和皮肤科医生组成的共识小组在亚洲召开现场会议，随后进行基于问卷的德尔菲程序。讨论了亚洲人在其原籍国和移民国的待遇问题。

结果：在大多数项目上，小组达成了多数共识。在亚洲人中确定了许多治疗适应症、策略和剂量，由于面部形态、解剖学和文化期望的不同，这些治疗指征、策略和剂量与以前描述的高加索人不同。该小组还制定了A型皮内肉毒毒素(“中间毒素”)、以小牛为范例的身体塑造以及腮腺减少的立场声明。虽然亚洲人以前被认为是美学上的同质群体，但这本出版物考虑了地区差异。提出了一种新的亚洲面部形态分类，以辅助治疗计划和实施。

结论：这是泛亚洲首次就A型肉毒毒素的美容使用达成共识，其独特的目标是优化所有地区全部或部分亚洲血统患者的治疗安全性和有效性。有关A型肉毒毒素的建议可以小心地推广到其他肉毒毒素制剂。